What RSU-related activity did the STANDARD BIOTOOLS (LAB) CFO report?

He reported the conversion of 70,183 restricted stock units into the same number of common shares on April 6, 2026. These RSUs are part of multi-year vesting schedules, where each unit entitles him to one share of STANDARD BIOTOOLS common stock upon vesting.

Standard BioTools (NASDAQ: LAB) CFO equity awards and tax share withholding

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported routine equity compensation activity and related tax withholding. On March 20, 2026, he received 323,173 shares of common stock and a stock option for 727,140 shares at an exercise price of $0.9846, vesting quarterly after May 20, 2026.

On April 6, 2026, 70,183 restricted stock units converted into the same number of common shares. Of these, 21,301 shares were withheld to cover tax obligations from a prior RSU grant, not sold in the market. After these transactions, he directly held 2,779,401 common shares.

Insider Trade Summary

70,183 shares exercised/converted

Mixed 5 txns

Insider Kim Hanjoon Alex

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	70,183	$0.00	--
Exercise	Common Stock	70,183	$0.00	--
Tax Withholding	Common Stock	21,301	$0.908	$19K
Grant/Award	Stock Option (Right to buy)	727,140	$0.00	--
Grant/Award	Common Stock	323,173	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 2,800,702 shares (Direct); Stock Option (Right to buy) — 727,140 shares (Direct)

Footnotes (1)

Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022. The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's common stock. On April 4, 2022, the Reporting Person was granted 280,732 RSUs, vesting in four equal annual installments beginning on April 4, 2023.

Key Figures

RSUs converted: 70,183 shares Shares withheld for taxes: 21,301 shares at $0.908 Shares held after transactions: 2,779,401 shares +2 more

5 metrics

RSUs converted 70,183 shares Restricted Stock Units into common stock on April 6, 2026

Shares withheld for taxes 21,301 shares at $0.908 Tax-withholding disposition on RSU vesting April 6, 2026

Shares held after transactions 2,779,401 shares Direct common stock ownership after April 6, 2026

New stock option grant 727,140 shares at $0.9846 Option grant on March 20, 2026, expiring March 20, 2036

New share award 323,173 shares Common stock grant on March 20, 2026

Key Terms

Restricted Stock Units, tax withholding obligations, Stock Option, vesting

4 terms

Restricted Stock Units financial

"Represents restricted stock units ("RSUs") that vest over four years..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"The shares were withheld from the reporting person to satisfy the tax withholding obligations..."

Stock Option financial

"The Option becomes exercisable as to 1/16th of the underlying shares..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vesting financial

"vest over four years, with 1/16 of the RSUs vesting on May 20, 2026..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

04/08/2026 - 09:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Hanjoon Alex

(Last)

(First)

(Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2026		A		323,173⁽¹⁾	A	$0	2,730,519	D
Common Stock	04/06/2026		M		70,183	A	$0	2,800,702	D
Common Stock	04/06/2026		F		21,301⁽²⁾	D	$0.908	2,779,401	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to buy)	$0.9846	03/20/2026		A		727,140		⁽³⁾	03/20/2036	Common Stock	727,140	$0	727,140	D
Restricted Stock Units	⁽⁴⁾	04/06/2026		M			70,183	⁽⁵⁾	⁽⁵⁾	Common Stock	70,183	$0	0	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022.

3. The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

4. Each RSU represents the contingent right to receive one share of the Issuer's common stock.

5. On April 4, 2022, the Reporting Person was granted 280,732 RSUs, vesting in four equal annual installments beginning on April 4, 2023.

	/s/ Hanjoon Alex Kim	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did STANDARD BIOTOOLS (LAB) CFO report?

The CFO reported equity awards and related vesting activity, not open-market trades. He received 323,173 common shares, a 727,140-share stock option, and 70,183 RSUs converted to stock, with some shares withheld to pay taxes on earlier RSU vesting.

How many STANDARD BIOTOOLS (LAB) shares does the CFO hold after this Form 4?

After the reported transactions, the CFO directly holds 2,779,401 shares of STANDARD BIOTOOLS common stock. This figure reflects RSU conversion, new share awards, and tax-related share withholding reported for March 20 and April 6, 2026.

What stock option grant did the STANDARD BIOTOOLS (LAB) CFO receive?

He received a stock option covering 727,140 shares of common stock at an exercise price of $0.9846 per share. The option begins vesting on May 20, 2026, and continues in equal quarterly installments until its expiration on March 20, 2036.

How were taxes handled on the CFO’s RSU vesting at STANDARD BIOTOOLS (LAB)?

On April 6, 2026, 21,301 shares were withheld to cover tax obligations from RSUs granted in April 2022. This F-code transaction is a tax-withholding disposition, meaning the shares were not sold on the open market but used to satisfy tax liabilities.